Fumagillin: Mechanism, Evidence & Application Benchmarks

Executive Summary: Fumagillin, supplied by APExBIO (A4407), acts as a covalent inhibitor of methionine aminopeptidase-2 (MetAP-2), suppressing endothelial cell proliferation and angiogenesis (source: product_spec). In vitro studies show that Fumagillin inhibits protozoan parasites at EC50 values between 10–100 mg/L (source: paper). Its crystalline form (MW 458.55, C26H34O7) is insoluble in water but highly soluble in DMSO and ethanol under defined conditions (source: product_spec). Tumor angiogenesis inhibition and in vivo efficacy in mouse models are established (source: workflow_recommendation). Proper storage at -20°C and avoidance of prolonged solution storage are required for chemical stability (source: product_spec).

Biological Rationale

Angiogenesis is a tightly regulated process crucial for tumor growth, wound healing, and tissue regeneration. Uncontrolled angiogenesis supports tumor progression and metastasis. Inhibition of endothelial cell proliferation—a central step in new blood vessel formation—remains a validated target in oncology and parasitology research (source: workflow_recommendation). Fumagillin's molecular selectivity for methionine aminopeptidase-2 links it to both cancer and anti-parasitic mechanisms, providing a unique cross-domain research asset.

Mechanism of Action of Fumagillin

Fumagillin forms a covalent bond with the active site of methionine aminopeptidase-2, causing irreversible enzymatic inhibition (source: product_spec). This blockade impedes post-translational processing of nascent proteins, resulting in cell cycle arrest in endothelial cells and inhibition of angiogenesis (source: workflow_recommendation). The same molecular target, MetAP-2, is implicated in the viability of several protozoan parasites, explaining Fumagillin’s antiparasitic effects in aquatic models (source: paper).

Evidence & Benchmarks

• Fumagillin inhibits protozoan Azumiobodo hoyamushi in vitro with EC50 values between 10–100 mg/L after 24 hours of exposure (source: paper).
• Tumor-induced angiogenesis is suppressed in vivo in mouse models treated with Fumagillin (source: workflow_recommendation).
• Fumagillin is insoluble in water but reaches solubility ≥81.3 mg/mL in DMSO and ≥2.58 mg/mL in ethanol with ultrasonic assistance (source: product_spec).
• For aquatic parasite assays, Fumagillin is first dissolved in DMSO, then diluted in culture medium; DMSO concentrations <1% do not affect outcomes (source: paper).
• Prolonged storage of reconstituted Fumagillin is not recommended due to solution instability (source: product_spec).

This article extends the practical focus of Fumagillin: Applied Workflows for Tumor Angiogenesis & Parasitic Assays by providing up-to-date numeric benchmarks and stability caveats. It also clarifies the selective mechanism discussed in Fumagillin: Translational Leverage in Angiogenesis & Parasitic Research with explicit EC50 data and handling requirements.

Applications, Limits & Misconceptions

Fumagillin is validated for inhibition of endothelial cell proliferation in angiogenesis models and for antiparasitic assays in aquatic species (source: paper). Its selectivity for MetAP-2 enables use in both cancer research and aquatic disease management.

Common Pitfalls or Misconceptions

• Not water soluble: Fumagillin must be dissolved in DMSO or ethanol; direct water dissolution is ineffective (source: product_spec).
• Instability in solution: Long-term storage of dissolved Fumagillin leads to loss of activity (source: product_spec).
• Not a broad-spectrum antiparasitic: Efficacy is moderate (EC50 10–100 mg/L) and limited to select protozoan species (source: paper).
• Human therapeutic use not established: Preclinical efficacy does not imply safety or effectiveness in humans (source: workflow_recommendation).
• Not interchangeable with analogs: TNP 470 is structurally related but exhibits distinct pharmacological properties (source: product_spec).

Workflow Integration & Parameters

Protocol Parameters

• in vitro antiparasitic assay | EC50 10–100 mg/L (24 h) | Azumiobodo hoyamushi | Benchmark for moderate efficacy | paper
• solubility in DMSO | ≥81.3 mg/mL | All research applications | Ensures high stock solution concentration | product_spec
• solubility in ethanol (ultrasound) | ≥2.58 mg/mL | All research applications | Alternative to DMSO; may require sonication | product_spec
• storage temperature | -20°C | All applications | Preserves compound integrity | product_spec
• stock solution stability | Use promptly after reconstitution | All applications | Prevents degradation and loss of potency | product_spec
• vehicle control | DMSO <1% in culture | In vitro assays | Vehicle does not confound biological readout | paper

For applied workflows in angiogenesis and parasite assays, see detailed protocols in Fumagillin: Applied Workflows for Angiogenesis & Antiparasitic Assays, which offers stepwise guidance and troubleshooting tips beyond this article’s evidence benchmarks.

Conclusion & Outlook

Fumagillin remains a well-characterized methionine aminopeptidase-2 inhibitor with validated roles in both angiogenesis and parasitic research domains. Product-specific handling and storage, as specified by APExBIO, are essential for experimental reproducibility. Future research should focus on refining application protocols for new model systems and further delineating the cross-domain boundaries of efficacy, as highlighted by both peer-reviewed and workflow literature (source: paper; product_spec).